BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients

NEXT STORY
Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Report 2021: A USD 10.4 Billion Market by 2028
PREV STORY
Longhorn Vaccines & Diagnostics and SiO2 Materials Science Team Up to Develop 12 Millimeter Sample Transport Media for Higher Volumes of Automated Virus Testing
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Horizon Pharma plc to Participate in BMO Prescriptions for Success Healthcare Conference

DUBLIN, Ireland, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical ...

author_avatar
NASDAQ Market News

VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit

CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”), a ...

author_avatar
NASDAQ Market News

Syndax Appoints Leading Experts to Scientific Advisory Board (SAB)

WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical ...

author_avatar
NASDAQ Market News